Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: VIVITROL (Naltrexone extended-release injectable suspension) Clear all
Completed Phase 2 Interventional Results available

VIVITROL as a Treatment for Cocaine and Alcohol Dependence

NCT00777062
View directory record Official record
Conditions
Cocaine Dependence, Alcohol Dependence
Interventions
VIVITROL (Naltrexone extended-release injectable suspension), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 2, 2026, 5:32 AM EDT
Recruiting Phase 4 Interventional

Naltrexone in AUD Reward Drinkers

NCT05028062
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholism
Interventions
XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Alcohol Disorder hOsPital Treatment Trial

NCT02478489
View directory record Official record
Conditions
Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder
Interventions
Oral naltrexone (PO-NTX), Extended-release injectable naltrexone (XR-NTX)
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

NCT03275350
View directory record Official record
Conditions
Opioid-use Disorder, Hiv
Interventions
Naltrexone Injectable Suspension, Treatment as usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Tarzana, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

NCT02978417
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone for extended-release injectable suspension, Oral naltrexone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

NCT00834080
View directory record Official record
Conditions
Opiate Dependence
Interventions
Medisorb naltrexone 380 mg
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Colton, California • Oceanside, California • Lauderhill, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 4 Interventional

Pre-Release VIVITROL for Opioid Dependent Inmates

NCT01563718
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
naltrexone for extended release injectable suspension
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

NCT00511836
View directory record Official record
Conditions
Alcohol Dependence
Interventions
VIVITROL 380 mg, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

NCT02537574
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Oceanside, California • Orange, California • Lauderhill, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 4 Interventional

Biomarkers of Injectable Extended Release Naltrexone Treatment

NCT02324725
View directory record Official record
Conditions
Heroin Dependence, Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 2, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Extended Release Naltrexone for Opioid-Dependent Youth

NCT01843023
View directory record Official record
Conditions
Drug Dependence
Interventions
Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
15 Years to 21 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 2, 2026, 5:32 AM EDT